drugset / Trial / NCT03380039
Clinical Study of CAR-BCMA T Cells in Patients With Refractory or Relapsed Multiple Myeloma
Unknown
6 enrolled
Xinhua Hospital, Shanghai Jiao Tong University School of Medicine
CARsgen Therapeutics Co., Ltd. · collab
NaSingle-groupOpen-labelTreatment
Summary
A single arm, open-label pilot study is designed to determine the safety, efficacy and cytokinetics of CAR-BCMA T cells in patients with BCMA-positive refractory or relapsed multiple myeloma.
Timeline
- Start
- 2017-10-13
- Primary completion
- 2020-07-02
- Completion
- 2023-07-02
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | CAR-BCMA T cells | Cell therapy | — | Intravenous |
| Background | Cyclophosphamide | Other / unclassified | — | — |
| Background | Fludarabine | Small molecule | — | — |